Biological treatment options for eosinophilic asthma, with consideration of markers of eosinophilic inflammation as predictors of treatment efficacy

Aleksandra Niemiec; Olga Branicka; Barbara Rymarczyk; Radosław Gawlik

doi:10.5114/pja.2024.135505

eISSN: 2391-6052
ISSN: 2353-3854

Alergologia Polska - Polish Journal of Allergology

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Artykuł przeglądowy

Biological treatment options for eosinophilic asthma, with consideration of markers of eosinophilic inflammation as predictors of treatment efficacy

Aleksandra Niemiec

¹

,

Olga Branicka

¹

,

Barbara Rymarczyk

¹

,

Radosław Gawlik

¹

Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland

Alergologia Polska – Polish Journal of Allergology 2024; 11, 1

DOI: https://doi.org/10.5114/pja.2024.135505

Data publikacji online: 2024/02/17

Pełna treść artykułu Pobierz cytowanie

Metryki PlumX:

Asthma is one of the most common allergic diseases affecting millions of people of all ages worldwide and influencing socioeconomic issues. Asthma, particularly uncontrolled asthma, not only reduces the quality of life but is also a major cause of disability for employment. The current pharmacologic strategy to therapy consists mostly of inhaled glucocorticoids and β-agonists, as well as leukotriene antagonists, long-acting muscarinic antagonists, and oral corticosteroids. However, the conventional therapy may provide insufficient control of severe asthma and may induce a number of adverse effects when used long-term. These limitations prompted the development of targeted biological drugs that inhibit the mediators involved in T helper 2-inflammation, which is linked to the pathogenesis of asthma, such as interleukin 4, 5, 9, 13 and immunoglobulin E. In many individuals, biological treatment provides significant relief and allows for the reduction or elimination of oral corticosteroids without compromising asthma control. However, some patients do not improve to their full potential. The cause of this phenomenon is unknown and requires further investigation.

Biological treatment options for eosinophilic asthma, with consideration of markers of eosinophilic inflammation as predictors of treatment efficacy

Aleksandra Niemiec 1 , Olga Branicka 1 , Barbara Rymarczyk 1 , Radosław Gawlik 1

Aleksandra Niemiec

¹

,

Olga Branicka

¹

,

Barbara Rymarczyk

¹

,

Radosław Gawlik

¹